TRVI
Trevi Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.90
+0.17%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$12.05
From 52W high−38.97%
Volume1.57M
Market cap$1.70B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$12.05
From 52W high
−38.97%
Volume
1.57M
Market cap
$1.70B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−27.0x
P/E (TTM)
—
RSI (14)
19.6
MomentumView details →
1D Return
+0.17%
YTD Return
−5.23%
SummaryUpdated Jun 1, 2026
Trevi Therapeutics, Inc. (NASDAQ:TRVI) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in New Haven, Connecticut. The company went public in May 2019 and focuses exclusively on developing <b>Haduvio</b>, an oral extended-release formulation of nalbuphine, to treat serious neurologically mediated conditions. Trevi operates under a licensing agreement with Endo Pharmaceuticals Inc. for the development and commercialization of nalbuphine hydrochloride-based products. The company is currently advancing multiple Phase 2 clinical trials targeting chronic cough conditions, representing a significant unmet medical need in respiratory medicine.
Similar companies
Latest newsMore news →
Trevi Therapeutics, Inc. announced pricing for its initial public offering of 8,333,334 shares at $14 per share.11d agoTrevi Therapeutics announced that Professor Marlies Wijsenbeek will present quality-of-life outcomes from the Phase 2b CORAL trial of nalbuphine ER at the ERS Congress 2026.55d agoTrevi Therapeutics began two clinical trials in Q2 2026 and plans to launch a third study in Q3 2026 for nalbuphine ER (Haduvio) in chronic-cough indications.73d ago